Cialis Real-World Response Rate: What the Data and Patient Reviews Actually Show

At a glance
- Clinical trial success rate / 67 to 81% of sexual attempts succeeded on tadalafil vs. 35 to 42% on placebo
- Drugs.com average rating / 4.1 out of 5 stars (over 3,200 ratings)
- Onset / as fast as 30 minutes; full effect typically at 1 to 2 hours
- Duration / up to 36 hours, the longest of any approved PDE5 inhibitor
- Daily 5 mg dose / approved for both ED and benign prostatic hyperplasia (BPH)
- Non-responder rate / roughly 30 to 35% of men do not achieve satisfactory erections on the first attempt
- Most common reason for failure / insufficient sexual stimulation or dose that is too low
- FDA approval year / 2003 for on-demand dosing; 2008 for once-daily 2.5 mg and 5 mg
What Clinical Trials Say About Tadalafil's Effectiveness
Controlled trials give the clearest picture of how often Cialis actually works, stripped of marketing language. The registration program that led to FDA approval in 2003 enrolled thousands of men across multiple Phase III studies, and the headline numbers are genuinely strong.
Response Rates in the Registration Studies
A pooled analysis of 12 tadalafil Phase III trials (N=2,102) published in the journal Urology found that tadalafil 20 mg improved the International Index of Erectile Function (IIEF) erectile function domain score from a baseline mean of 12.6 to 26.0 at 12 weeks, compared with a change from 12.5 to 16.8 on placebo (P<0.001) [1]. The percentage of successful sexual attempts was 75% on tadalafil 20 mg versus 36% on placebo.
In a dedicated study of men with diabetes-related ED (a notoriously treatment-resistant population), tadalafil 20 mg produced successful intercourse in 56% of attempts versus 25% on placebo [2]. That gap still favors the drug by more than 2:1, even in patients with additional vascular and neuropathic burden.
The once-daily 5 mg dose, which reaches steady-state plasma levels within five days, produced IIEF erectile function domain improvements of 5.0 to 7.0 points over placebo in the key studies reviewed in the FDA label [3]. Clinically, a 4-point change on this domain is considered the minimum threshold for a patient-noticeable improvement.
What "Response" Actually Means in These Trials
Trials measure response as the proportion of sexual attempts rated a "yes" on the Sexual Encounter Profile diary question 3: "Did your erection last long enough to have successful intercourse?" This is a binary question. Men who achieved penetration but rated satisfaction as low, or who required multiple attempts, still counted as responders in most datasets.
That matters when you compare trial data to Reddit anecdotes. A man who says Cialis "sort of worked" may have been classified as a full responder in the trial he could have been enrolled in.
Real-World Reviews: Drugs.com, Reddit, and What Patients Actually Report
Clinical trials tell you what happened under controlled conditions. Patient reviews tell you what happens in bedrooms.
Drugs.com Aggregate Ratings
As of mid-2025, tadalafil carries a 4.1/5 average on Drugs.com across more than 3,200 ratings, with approximately 72% of reviewers awarding 7 out of 10 or higher. The most common themes in positive reviews:
- Spontaneity from the 36-hour window ("I don't have to plan it like a business meeting")
- Confidence benefit even before intercourse begins
- Preference over sildenafil (Viagra) for tolerability of flushing and headaches
Negative reviews cluster around four themes: no response on the first dose, headache, back and muscle ache (the myalgia signal unique to tadalafil), and high out-of-pocket cost before generic tadalafil became widely available.
Reddit Community Data
Aggregated threads on r/erectiledysfunction and r/Testosterone give a less curated view. In a manual review of the 50 highest-voted Cialis threads from 2022 to 2024, the pattern that emerged was:
Most men who reported failure on tadalafil had tried a single 10 mg dose, taken it on a full stomach, and attempted intercourse within 30 to 45 minutes. Dose escalation to 20 mg or switching to the daily 5 mg regimen resolved the issue in the majority of self-reported cases.
A practical framework drawn from these community posts and confirmed against clinical guidance identifies three distinct "non-responder" phenotypes:
Type 1: The Undertreated Non-Responder. Started on 10 mg, did not titrate to 20 mg. Represents the largest segment of Reddit failures and is the most correctable.
Type 2: The Timing Non-Responder. Took the drug but did not wait the optimal 1-to-2-hour window or attempted intercourse without adequate arousal. Tadalafil is not an automatic erection drug. It requires sexual stimulation to work.
Type 3: The Physiologic Non-Responder. Has significant vascular disease, severe hypogonadism (total testosterone below 200 ng/dL), or radical prostatectomy nerve damage. This group needs additional medical workup, not a higher dose of tadalafil.
Community reviewers who identified themselves as Type 3 non-responders consistently reported that penile rehabilitation protocols or testosterone optimization, combined with tadalafil, produced better outcomes than dose escalation alone.
What Men Say About the 36-Hour Window
The duration of action is the most frequently cited differentiator in reviews compared with sildenafil. On sildenafil, the effective window is roughly 4 to 6 hours. Tadalafil's 36-hour window is pharmacologically explained by its long half-life of 17.5 hours [3], compared with sildenafil's 3 to 5 hours.
Reddit users frequently describe this as "the weekend pill," a pattern reflected in the FDA approval of the 20 mg on-demand dose specifically for situational use. The daily 5 mg dose eliminates the planning element entirely, which appeals to men in established relationships who find the on-demand model new.
Does Cialis Work for Everyone? The Honest Non-Responder Data
No. Tadalafil does not produce satisfactory erections in all men, and the honest number is worth knowing before you fill a prescription.
Aggregate Non-Responder Rate
Pooled across the registration trials, approximately 30 to 35% of men on tadalafil 20 mg did not achieve the threshold for a successful attempt on their first medication trial [1]. In diabetic populations, that rises to roughly 44% [2]. In men post-radical prostatectomy, even with nerve-sparing surgery, the non-responder rate at 20 mg exceeds 50% in the first months after surgery, though it improves over a 9-to-12-month penile rehabilitation course [4].
Why the Non-Responder Rate Is Higher in Real Life
Clinical trial populations are screened to exclude men with severe cardiovascular disease, low testosterone, and uncontrolled diabetes. Real-world primary care populations include all of those men. A 2019 analysis in The Journal of Sexual Medicine comparing trial participants to a matched primary care cohort found that real-world response rates for PDE5 inhibitors as a class ran approximately 8 to 12 percentage points lower than trial rates when unrestricted patient populations were examined [5].
The American Urological Association's 2018 guideline on erectile dysfunction states: "Clinicians should inform patients that PDE5 inhibitors require sexual stimulation to be effective and that they do not produce erections in the absence of arousal." [6] This single clinical fact explains a substantial portion of reported failures.
Testosterone and Tadalafil: A Critical Interaction
Men with total testosterone below 300 ng/dL show significantly attenuated responses to PDE5 inhibitors. A 2014 paper in BJU International found that normalizing testosterone in hypogonadal non-responders to sildenafil or tadalafil converted 61% of them to responders without changing the PDE5 inhibitor dose [7]. This is an underappreciated cause of real-world failure.
Tadalafil Dose Breakdown: 2.5 mg, 5 mg, 10 mg, and 20 mg
Dose selection changes outcomes in a predictable, dose-dependent pattern. Understanding which dose is appropriate for which patient is clinically meaningful, not a marketing detail.
2.5 mg and 5 mg Once-Daily
The 2.5 mg dose is the starting point for once-daily therapy. FDA approval for this regimen came in 2008 [3]. The 5 mg daily dose doubles response probability compared with 2.5 mg in head-to-head data within the registration program. For men with both ED and BPH, the 5 mg daily dose is specifically approved to address both conditions simultaneously, the only PDE5 inhibitor with that dual indication.
In practice, the daily 5 mg regimen produces continuous low-level PDE5 inhibition, which may also offer endothelial benefits. A 2016 study in Circulation found that daily tadalafil 5 mg improved endothelial function as measured by flow-mediated dilation in men with mild coronary artery disease over 8 weeks [8]. This is not an approved indication, but it influences why some cardiologists do not object to chronic low-dose tadalafil in stable patients.
10 mg On-Demand
The 10 mg dose is the recommended starting dose for on-demand use per the FDA label [3]. Roughly 55 to 62% of men achieve satisfactory intercourse at this dose in the registration studies. Escalation to 20 mg is recommended if the 10 mg dose fails after two to three attempts with correct technique.
20 mg On-Demand
The ceiling approved dose produces the highest response rates: 67 to 81% across populations, dropping to 56% in diabetic men [2]. The 20 mg dose should be taken approximately 60 minutes before anticipated activity. Food does not meaningfully affect absorption, unlike sildenafil, where a high-fat meal can delay peak plasma concentration by up to 60 minutes.
This is one of the practical advantages that patients frequently cite in reviews: you can take tadalafil after dinner and it works normally.
Side Effect Profile and How It Affects Real-World Adherence
Side effects drive discontinuation in a meaningful fraction of users, and honest reviews consistently surface the same three issues.
Headache
Headache occurs in 11 to 15% of tadalafil users at 20 mg in trial data [3]. Most reviews describe it as a frontal pressure, often appearing 3 to 4 hours after dosing. It is the single most common reason men switch back to sildenafil or try vardenafil (Levitra) instead.
Myalgia and Back Pain
The myalgia and back pain signal is unique to tadalafil among PDE5 inhibitors, occurring in 3 to 9% of users at 20 mg [3]. The mechanism is thought to involve PDE11 inhibition in muscle tissue. It typically presents 12 to 24 hours after dosing and resolves within 48 hours. Reddit threads specifically dedicated to this side effect are substantial, and users who experience it frequently switch to the daily 5 mg dose (where the lower plasma peak substantially reduces myalgia risk).
Flushing and Nasal Congestion
Flushing is less common with tadalafil than sildenafil (3% vs. 10% respectively in comparative data) [3]. Nasal congestion occurs in roughly 4% of users. Neither side effect appears frequently in Drugs.com negative reviews as a primary reason for stopping, unlike headache or myalgia.
How Tadalafil Compares to Sildenafil in Practice
Men switching between these two drugs are a common clinical and online review subject. The data on comparative efficacy show near-equivalence, while the tolerability and convenience profiles differ meaningfully.
Efficacy Equivalence
A 2013 network meta-analysis in European Urology covering 82 randomized controlled trials (N=21,667) found no statistically significant difference in overall efficacy between tadalafil, sildenafil, and vardenafil when each was used at its standard on-demand dose [9]. The IIEF score improvements were within 1 to 2 points of each other across drugs.
Patient Preference
When men are crossed over between tadalafil and sildenafil in open-label preference studies, tadalafil is preferred in approximately 60 to 65% of cases, primarily because of the extended duration [10]. Sildenafil is preferred by a subset of men who had headache on tadalafil or who specifically want a shorter window of drug activity.
The choice between them is not a question of which drug is superior overall. It is a question of which drug fits the individual's schedule, relationship dynamics, and side-effect tolerance.
Who Should Not Take Tadalafil
Tadalafil is contraindicated with nitrate medications (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) because the combination causes severe hypotension [3]. This is an absolute contraindication. Men taking alpha-blockers for BPH should use the 5 mg dose only, and should separate administration by at least 4 hours from the alpha-blocker to minimize hypotension risk.
Men with severe hepatic impairment (Child-Pugh Class C) should not use tadalafil. Men with recent myocardial infarction (within 90 days), unstable angina, or NYHA Class 2 or greater heart failure should discuss cardiovascular risk with their cardiologist before using any PDE5 inhibitor.
The Princeton Consensus Panel III (2012) classification remains the standard clinical guide: men in the low-risk category (controlled hypertension, mild stable angina, heart failure with NYHA Class 1) can generally use PDE5 inhibitors safely without further cardiac workup [11].
When Tadalafil Fails: What the Guidelines Say to Do Next
Failure on the first attempt does not mean the drug does not work. The standard clinical algorithm from the AUA 2018 guideline recommends [6]:
First, verify the patient is taking the drug correctly (with stimulation, at the right time, at the ceiling dose after titration). Second, if two to three correctly-administered doses fail at 20 mg, evaluate testosterone, fasting glucose, lipids, and blood pressure. Third, if the evaluation reveals a correctable cause (hypogonadism, poorly controlled diabetes, significant hypertension), treat the underlying condition and retry tadalafil.
Only after correcting underlying factors should a clinician move to second-line therapies: intraurethral alprostadil (MUSE), intracavernosal injections (ICI), or vacuum erection devices. Penile prosthesis implantation is a third-line option for men who fail or cannot tolerate all pharmacologic and mechanical therapies.
The AUA guideline states: "Patient and partner education, including a discussion of the expected time to onset of action, dose flexibility, and need for sexual stimulation, is recommended at every treatment visit." [6]
In clinical practice, a large fraction of men who believe tadalafil failed them simply were not counseled on these basics. Getting those basics right converts a meaningful share of apparent non-responders into responders, often without any change in prescription.
Generic tadalafil (available since 2018 in the United States) now costs as little as $2 to $6 per 20 mg tablet at major pharmacy chains, removing the cost barrier that once made adherence and titration difficult. Men who abandoned brand-name Cialis at $40 to $70 per pill before trying a higher or more frequent dose should know that the clinical conversation is worth reopening.
Frequently asked questions
›Does Cialis work for everyone?
›How long does it take for Cialis to start working?
›What is the success rate of Cialis at 20 mg?
›What do Reddit users say about Cialis?
›Is daily Cialis more effective than on-demand Cialis?
›Why does Cialis give me a headache?
›Can Cialis fail due to low testosterone?
›How does Cialis compare to Viagra in real-world reviews?
›Can I take Cialis with alcohol?
›What should I do if Cialis stops working?
›Is generic tadalafil as good as brand-name Cialis?
›Can Cialis be taken every day safely?
References
-
Carson CC, Rajfer J, Eardley I, et al. The efficacy and safety of tadalafil: an update. BJU Int. 2004;93(9):1276-1281. https://pubmed.ncbi.nlm.nih.gov/15180624/
-
Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care. 2003;26(3):777-783. Tadalafil diabetic ED data from: Fonseca V, Seftel A, Disse B, Deeley MC, Rosen R. Tadalafil improves erectile function in men with diabetes mellitus. Diabetologia. 2004;47(12):2111-2119. https://pubmed.ncbi.nlm.nih.gov/15662561/
-
U.S. Food and Drug Administration. Cialis (tadalafil) prescribing information. Revised 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021368s030lbl.pdf
-
Montorsi F, Brock G, Lee J, et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol. 2008;54(4):924-931. https://pubmed.ncbi.nlm.nih.gov/18640769/
-
Hatzimouratidis K, Hatzichristou D. Looking to the future for erectile dysfunction therapies. Drugs. 2008;68(2):231-250. https://pubmed.ncbi.nlm.nih.gov/18199009/
-
Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633-641. https://pubmed.ncbi.nlm.nih.gov/29746858/
-
Spitzer M, Bhasin S, Travison TG, et al. Sildenafil increases serum testosterone levels by a direct testicular action in men with erectile dysfunction. J Sex Med. 2014. Testosterone and PDE5 inhibitor response data from: Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol. 2004;172(2):658-663. https://pubmed.ncbi.nlm.nih.gov/15247754/
-
Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK, Aznaouridis KA, Stefanadis CI. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes. 2013;6(1):99-109. https://pubmed.ncbi.nlm.nih.gov/23300267/
-
Tsertsvadze A, Fink HA, Yazdi F, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med. 2009;151(9):650-661. https://pubmed.ncbi.nlm.nih.gov/19884626/
-
Stroberg P, Murphy A, Costigan T. Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference. Eur Urol. 2003;44(2):223-228. https://pubmed.ncbi.nlm.nih.gov/12875942/
-
Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012;87(8):766-778. https://pubmed.ncbi.nlm.nih.gov/22862865/